Jackson S. Turner

TL;DR: In this article, using monoclonal antibodies (mAbs), animal immune sera, human convalescent sera and human sera from recipients of the BNT162b2 mRNA vaccine, the authors report the impact on antibody neutralization of a panel of authentic SARS-CoV-2 variants including a B.1.7 isolate, chimeric strains with South African or Brazilian spike genes and isogenic recombinant viral variants.

TL;DR: In this article, the authors examined antigen-specific B-cell responses in peripheral blood and draining lymph nodes in 14 individuals who had received 2-doses of BNT162b2, an mRNA-based vaccine that encodes the full-length SARS-CoV-2 spike (S) gene1.

TL;DR: Transduced replication-defective adenoviruses encoding human ACE2 via intranasal administration into BALB/c mice and established receptor expression in lung tissues and passive transfer of a neutralizing monoclonal antibody reduced viral burden in the lung and mitigated inflammation and weight loss.

TL;DR: In this paper, the authors show that mild SARS-CoV-2 infection induces long-lived bone marrow plasma cells that correlate with anti-SARS-coV2 spike protein antibody titres in individuals who have recovered from COVID-19.

TL;DR: Immunologic evaluation shows that most COVID-19 patients exhibit targeted immunosuppression compared to patients with influenza, and single-cell transcriptional profiling revealed profound suppression of interferon signaling among patients with CO VID-19.